The Anti-VEGF Market is expanding across major geographical regions as healthcare systems respond to the increasing burden of retinal diseases. Market Research Future estimates that the market will grow from USD 27.1 billion in 2025 to USD 41.3 billion by 2035, with a CAGR of 4.3%.

North America currently represents the largest regional market, accounting for more than 45.03% of global revenue in 2024. Strong healthcare infrastructure, biotechnology development, regulatory support, and high adoption of advanced ophthalmic therapies contribute to the region's leadership. The United States represents a major contributor to regional demand.

Europe is another significant market, valued at approximately USD 7.79 billion in 2024. Well-established healthcare systems, research investments, and regulatory frameworks support the development and adoption of anti-VEGF treatments across countries such as Germany, France, and the United Kingdom.

Asia-Pacific is witnessing rapid growth, supported by increasing healthcare expenditure, rising awareness of retinal diseases, improving healthcare access, and an aging population. China and Japan are important markets within the region.

The Middle East and Africa represent an emerging opportunity. Although infrastructure and regulatory differences remain challenges, increasing healthcare investment and awareness could support future market development.

Overall, regional expansion, innovative therapies, biosimilars, personalized medicine, and improved treatment accessibility are expected to shape the future of the Anti-VEGF Market.